ALVO OAKTREE ACQUISITION CORP II

Viðskipti stjórnenda og tengdra aðila

Viðskipti stjórnenda og tengdra aðila

Í viðhengi er tilkynning um viðskipti stjórnenda og tengdra aðila sem lögð var inn til birtingar hjá fjármálaeftirliti Lúxemborgar, Luxembourg Commission de Surveillance du Secteur Financier (CSSF), um kaup Alvogen Lux Holdings S.ár.l. á 201,000 hlutum í Alvotech á genginu 1.277,38 krónur á hlut. Alvogen Lux Holdings er annar stærsti hluthafi Alvotech. Stærstu hluthafar Alvogen Lux Holdings eru fjárfestingasjóðirnir CVC (40%), Aztiq (30%) og Temasek (20%).

Viðhengi



EN
13/05/2025

Underlying

ALVOOAKTREE ACQUISITION CORP II

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OAKTREE ACQUISITION CORP II

 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results REYKJAVIK, ICELAND (March 4, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its fourth quarter and full year 2025 financial and operating results on Wednesday, March 18, 2026, after the U.S. markets close. The Company will also host a conference call with a live Q&A on Thursday, March 19, 2026 at 08:00 EST (12:00 GMT, 13:00 CET). To listen to the webcast, ...

4h / 33m 1 EN
 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results REYKJAVIK, Iceland, March 04, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its fourth quarter and full year 2025 financial and operating results on Wednesday, March 18, 2026, after the U.S. markets close. The Company will also host a conference call with a live Q&A on Thursday, March 19, 2026 at 08:00 EST (12:00 GMT, 13:00 CET). To lis...

4h / 33m 1 EN
 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Alvotech kynnir uppgjör ársins 2025 þann 19. mars nk.

Alvotech kynnir uppgjör ársins 2025 þann 19. mars nk. REYKJAVÍK (4. Mars 2026) – Alvotech (NASDAQ: ALVO) mun birta uppgjör ársins 2025 og fjórða ársfjórðungs miðvikudaginn 18. Mars 2026, eftir lokun markaða í Bandaríkjunum. Fundur til kynningar á uppgjörinu verður sendur út í beinu streymi og hefst kl. 12, fimmtudaginn 19. Mars 2026. Til að hlusta á streymið, skráið ykkur hér: Hlekkur fyrir þá sem hyggjast beina spurningum til stjórnenda:   Glærur og annað kynningarefni verða aðgengileg á  fyrir fundinn. Nánari upplýsingar FjölmiðlatengslBenedikt StefánssonSarah MacLeod Fjárfestatengsl...

4h / 33m 1 EN
 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Transactions of Managers and Closely Associated Persons

Transactions of Managers and Closely Associated Persons Attached are copies of two filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons. ATP Holdings ehf. announced a sale of 2,701,617 shares in Alvotech on January 30, 2026, and Aztiq Pharma Partners S.à r.l. ("Aztiq") announced the acquisition of 2,701,617 shares in Alvotech on January 30, 2026. ATP Holdings ehf. belongs to the Aztiq group and the transaction was thus a transfer of shares within the group. The announcements related to the same t...

February 26, 2026 1 EN
 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Viðskipti stjórnenda og tengdra aðila

Viðskipti stjórnenda og tengdra aðila Í viðhengi eru tvær tilkynningar um viðskipti stjórnenda og tengdra aðila sem lagðar voru inn til birtingar hjá fjármálaeftirliti Lúxemborgar, Luxembourg Commission de Surveillance du Secteur Financier (CSSF). ATP Holdings ehf. tilkynnti um sölu á 2.701.617 bréfum þann 30. janúar sl. og Aztiq Pharma Partners S.à r.l. ("Aztiq") um kaup á 2.701.617 bréfum þann 30. janúar sl. ATP Holdings ehf. er í sömu samstæðu og Aztiq og var því um að ræða flutning bréfanna innan samstæðunnar. Tilkynningarnar vörðuðu sömu viðskipti og verð bréfanna í viðskiptunum var 4,...

February 26, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch